Showing results (101-110 of 251) with videos related to
Sort By:
Pageof 26
Digestive Diseases and Sciences|June 20, 2020
Improving All-Cause Inpatient Mortality After Percutaneous Endoscopic GastrostomyDaniel J Stein, Matthew B Moore, Gila Hoffman, et al.Journal of Managed Care & Specialty Pharmacy|February 26, 2014
Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysisJennifer Devlen, Kathleen Beusterien, Linnette Yen, et al.Scandinavian Journal of Gastroenterology|July 6, 2026
Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitisStephen Le Breton, Aditya Mithal, Tasnim Ahmed, et al.Journal of Digestive Diseases|November 10, 2017
C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximabMarie P Boyle, Alan C Moss, Aoibhlinn M O'Toole, et al.Journal of Crohn'S & Colitis|March 29, 2018
Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel DiseaseKonstantinos Papamichael, Ravy K Vajravelu, Byron P Vaughn, et al.Inflammatory Bowel Diseases|September 29, 2011
Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapyByron P Vaughn, Glen A Doherty, Shiva Gautam, et al.Inflammatory Bowel Diseases|August 28, 2015
Adherence to Rectal Mesalamine in Patients with Ulcerative ColitisMarie Boyle, Amanda Ting, Didia B Cury, et al.Digestive Diseases and Sciences|June 18, 2009
Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximabAlan C Moss, Kyung Jo Kim, Nielsen Fernandez-Becker, et al.Inflammatory Bowel Diseases|January 11, 2014
The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual modelJennifer Devlen, Kathleen Beusterien, Linnette Yen, et al.Inflammatory Bowel Diseases|May 17, 2017
Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel DiseaseAbhijeet Yadav, Joshua Foromera, Ilana Feuerstein, et al.Pageof 26